Supplementary file 1_The diversity of cytomegalovirus among blood donors and transplant re

71 hematopoietic stem cell recipients received CMV-specific immunoglobulin prophylaxis in a single-center ambispective study. The dataset likely contains clinical outcomes, pharmacokinetic data, and immunological readouts comparing European and non-European cohorts. Stefania Braidotti published the data on figshare in April 2026 under a CC-BY-4.0 license.

Use Cases

• Compare viral clearance rates based on CMV-specific immunoglobulin prophylaxis.
• Analyze ethnic disparities in clinical outcomes based on patient cohort data.
• Model pharmacokinetics based on immunoglobulin terminal half-life data.
• Evaluate immune reconstitution metrics based on immunological readouts.
• Associate hospital stay duration with prophylaxis strategy based on clinical records.

Strengths

• Includes pharmacokinetic data with a terminal half-life of approximately 15 days.
• Compares outcomes across two distinct ethnic cohorts (European vs. non-European).
• Contains results from a study group of 71 recipients and a historical control group.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to a single-center study.

Provenance

Source

figshare

Collection Method

Post hoc analysis of a single-center ambispective study.

Freshness

Last updated 2026-04-29 05:57:53; freshness should be verified.